Predictive Oncology strengthens pharmaceutical and biotech offering; announces retirement of CEO and chairman J Melville EngleProactive Investors • 09/19/22
Predictive Oncology Strengthens Offerings with GMP Lab and Addition of Leading Expert in Formulation DevelopmentGlobeNewsWire • 09/19/22
Predictive Oncology announces retirement of its chief executive officer and chairman, J. Melville EngleProactive Investors • 09/19/22
Predictive Oncology ends 2Q 2022 with strong balance sheet and solid cash positionProactive Investors • 08/12/22
Traders News Source Senior Editor Mark Roberts Interviews J. Melville Engle, CEO and Chairman of the Board, Predictive OncologyAccesswire • 08/09/22
Predictive Oncology appoints Julia Kirshner as its new Chief Scientific OfficerProactive Investors • 07/26/22
Predictive Oncology Strengthens Business with Appointment of a Chief Scientific Officer and Consolidation and Expansion of its Research and Development ArmGlobeNewsWire • 07/26/22
Predictive Oncology closes two concurrent offerings raising gross proceeds of $7.2MProactive Investors • 05/19/22
Predictive Oncology Announces Closing of $7.2 Million Registered Direct OfferingsGlobeNewsWire • 05/18/22
Predictive Oncology reports sharply higher consolidated revenue in 1Q 2022Proactive Investors • 05/13/22
Predictive Oncology has an AI-driven drug discovery platform to improve cancer treatments and speed up drug developmentProactive Investors • 05/10/22
Predictive Oncology announces Theresa Ferguson as the company's senior director of MarketingProactive Investors • 04/26/22
Marketer with over 20 years of experience selected to head up marketing at Predictive OncologyGlobeNewsWire • 04/26/22
Predictive Oncology strengthens balance sheet in 2021; zPREDICTA acquisition highlights financial yearProactive Investors • 04/01/22
Predictive Oncology Reports Year End 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 03/31/22
Predictive Oncology set to market its flagship artificial intelligence drug discovery platformProactive Investors • 01/27/22
HC Wainwright reiterates ‘Buy' rating on Predictive Oncology and $5 price targetProactive Investors • 01/25/22